The Challenges of Scaling Stem Cell Production
BioLamina CEO Klaus Langhoff-Roos discusses the difficulties of scaling stem cell production from lab plates to bioreactors, highlighting the balance between cost, risk, and speed in advancing laminin-based technologies for next-generation cell and gene therapies.
“oftentimes there is in biotech digital ones and zeros, but most of what you do is in the gray zone”
Langhoff-Roos faced a producer cell line that worked, but not well enough, emphasizing the need for careful consideration in advancing these technologies.
Author's summary: Scaling stem cell production poses significant challenges.